Role of endothelial cells in the pathogenesis of diabetic microangiopathy

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 9, Issue 5, 1996, Pages 273-289

  Rotella, C M ^a,b   Giannini, S ^a   Galli, G ^b   Cresci, B ^a   Tanini, A ^b  

^a Dept of Clinical Pathophysiology ^*  (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Diabetic microangiopathy; Endothelial cells; Hyperglycaemia; Nephropathy; Retinopathy

Indexed keywords

ALDEHYDE REDUCTASE; DIACYLGLYCEROL; NITRIC OXIDE; POLYOL; PROTEIN KINASE C;

BASEMENT MEMBRANE; CELL JUNCTION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA; MOLECULAR BIOLOGY; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0029804042     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. La Selva M., Beltramo E., Passera P., Porta M., Molinatti G.M.: The role of endothelium in the pathogenesis of diabetic microangiopathy. Acta Diabetol 30: 190-200, 1993.
2. Manuelli C., Galli G., Biondi P., Perri P., Melani P., Zonefrati R., Vannelli B., Casini A., Surrenti C., Schuppan D., Conti A., Brandi M.L., Rotella C.M.: Characterization and cloning of bovine retinal endothelial cells (BREC) in long term culture. Diab. Nutr. Metab. 8: 281-291, 1995.
3. Streeten E.A., Brandi M.L.: Biology of bone endothelial cells. Bone Miner. 10: 85-94, 1990.
4. Rotella C.M., Galli G., Casini A., Bianchi S., Mannucci E., Cresci B., Shuppan D., Conti A., Brandi M.L.: Release of extracellular matrix components by bovine bone endothelial cells in continuous culture. Biochem. Biophys. Res. Commun. 190: 502-508, 1993.
5. Galli G., Casini A., Bianchi S., Mannucci E., Cresci B., Surrenti C., Schuppan D., Conti A., Brandi M.L., Rotella C.M.: Effects of insulin and glucose on the growth and the release of extracellular matrix components by bovine bone endothelial cells. Endocrine J. 2: 559-566, 1994.
6. Dejana E., Corada M., Lampugnani M.G.: Endothelial cell-to-cell junction. FASEB J. 9: 910-918, 1995.
7. Rubin S.A., Levin E.R.: The endocrinology of vasoactive peptides: synthesis to function. J. Clin. Endocrinol. Metab. 78: 6-10, 1994.
8. Sokolowsky M.: Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Pharmac. Ther. 68: 435-471, 1995.
9. Palmer R.M.J., Ashton D.S., Moncada S.: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-668, 1988.
10. De Nicola L., Blantz R.C., Gabbai F.B.: Nitric oxide and angiotensin II. J. Clin. Invest. 89: 1248-1256, 1992.
11. Moncada S.,Gryglewsky R., Bunting S., Vane J.R.: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665, 1976.
12. Ogawa S., Gerlach H., Esposito C., Pasagian-Macanley A., Brett J., Stern D.: Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. J. Clin. Invest. 85: 1090-1098, 1990.
13. Stern D.M., Kaiser E., Nawroth P.P.: Regulation of the coagulation system by vascular endothelial cells. Haemosiasis 18: 202-214, 1988.
14. Schleef R.R., Loskutoff D.J.: Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 18: 328-341, 1988.
15. Colucci M., Balconi G., Lorenzet R., Pietra A., Locati D., Donati M.D., Semeraro N.; Cultured human endothelial cells generate tissue factor in response to endotoxin. J. Clin. Invest. 71: 1893-1896, 1983.
16. Boes M., Dake B.L., Bar R.S.: Interactions of cultured endothelial cells with TGF-β, bFGF, PDGF and IGF-I. Life Science 48: 811-821, 1991.
17. Moser D.R., Lowe W.L. Jr, Dake B.L, Booth B.A., Boes M., Clemmons D.R., Bar R.S.: Endothelial cells express insulin-like growth factor binding proteins 2 to 6. Mol. Endocrinol. 6: 1805-1814, 1992.
18. Giannini S., Cresci C., Manuelli C., Pala L., Rotella C.M.: An insulin-like growth factor-I receptor independent mechanism regulates insulin-like growth factor binding proteins in bovine retinal endothelial cells. Exp. Clin. Endocrinol. Diab. 104 (Suppl. 2): 97-99, 1996.
19. Ferrara N., Hauck K., Jaeman L., Leung D.W.: Molecular and biological properties of the vascular endothelial growth family of proteins. Endocrine Rev. 13: 18-31, 1992.
20. Roberts W.G., Palade G.E.: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108: 2369-2379, 1995.
21. Thieme H., Aiello L.P., Takagi H., Ferrara N., King G.L.: Comparative analysis of vascular endothelial growth factor receptor on retinal and aortic vascular endothelial cells. Diabetes 44: 98-130, 1995.
22. Jakeman L.B., Winer J., Bennett G.L., Altar C.A., Ferrara N.: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89: 244-253, 1992.
23. Pepper M.S., Ferrara N., Orci L., Montesano R.: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181: 902-906, 1991.
24. King G.L., Goodman A.D., Buzney, S.: Receptors and growth promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. 75: 1028-1035, 1985.
25. Kahn B.B.: Facilitative glucose transporters: regulatory mechanisms and disregulation in diabetes. J. Clin. Invest. 89: 1367-1374, 1992.
26. Aumailley M.: Structure and supramolecular organization of basement membranes. Kidney Int. 47 (Suppl. 49): S4-S7, 1995.
27. Greene D.A., Lattimer S.A., Sima A.A.F.: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med. 316: 599-606, 1987.
28. Menè P., Pugliese G., Pricci F., Di Mario U., Cinotti G.A., Pugliese F.: High glucose inhibits cytosolic calcium signalling in cultured rat mesangial cells. Kidney Int. 43: 585-589, 1993.
29. Lee T-S., Saltsman A., Ohashi H., King G.L.; Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complication. Proc. Natl. Acad. Sci. USA 86: 5141-5145, 1989.
30. De Rubertis F.R., Craven P.A.: Activation of protein kinase C in glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 43: 1-8, 1994.
31. Cagliero E., Roth T., Roy S., Lorenzi M.: Mechanisms of high glucose induced overexpression of basement membrane components in cultured human endothelial cells. Diabetes 40: 102-110, 1991.
32. Pricci F., Pugliese G., Mene P., Romano G., Romeo G., Galli G., Casini A., Rotella C.M., Di Mario U., Pugliese F.: Regulatory role of eicosanoids in extracellular matrix overproduction induced by prolonged exposure to high glucose in cultured rat mesangial cells. Diabetologia 39: 1055-1062, 1996.
33. 2+ response and EDRF formation in vascular endothelial cells. Diabetes 43: 984-991, 1994.
34. Vlassara H., Bucala R., Striker L.J.: Pathogenic effects of advanced glycosilation: biochemical, biological, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151, 1994.
35. Brownlee M.: Glycosylation products as toxic mediators of diabetic complications. Annu. Rev. Med. 42: 159-166, 1991.
36. Bucala R., Tracey K.J., Cerami A.: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J. Clin. Invest. 87: 432-438, 1991.
37. Corbett J.A., Tilton R.G., Chang K., Kasan K., Ido Y., Wang J.L., Sweetland M.A., Lancaster Jr. J.R., Williamson J.R., Mc Daniel M.L.: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556, 1992.
38. Schmidt A.M., Hori O., Brett J., Van S.D., Wautier J.L., Stern D.: Cellular receptors for advanced glycation end products. Arterioscler. Thromb. 14: 1521-1528, 1994.
39. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegart H., Hurley W., Clauss M., Wang F., Pan Y.C., Tsang T., Stern D.: Isolation and characterization of binding proteins for advanced glycation end products from lung tissue which are present on the endothelial cell surface. J. Biol. Chem. 267: 14987-14997, 1992.
40. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan J.C., Elliston K., Stern D., Shaw A.: Cloning and expression of RAGE: a cell surface receptor for advanced glycation end products of proteins. J. Biol. Chem. 267: 14998-15004, 1992.
41. Schmidt A.M., Hori O., Chen J.K., Feng Li J., Crandail J., Zhang J., Cao R., Yan S.D., Brett J., Stern D.: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J. Clin. Invest. 96: 1395-1403, 1995.
42. Pugliese G., Tilton R.G., Williamson J.R.: Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab. Rev. 7: 35-59, 1991.
43. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., Van Den Enden M., Kilo C., Tilton R.G.: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993.
44. Tilton R.G., Miller E.J.. Kilo C., Williamson J.K.: Pericyte form and distribution in cat retinal and uveal capillaries. Invest. Ophthalmol. Vis. Sci. 26: 60-73, 1985.
45. Feldt-Ramussen B.: Increased transcapillary escape rate of albumin in type 1 (insulin dependent) diabetic patients with microalbuminuria. Diabetologia 28: 282-286, 1986.
46. Sorbinil retinopathy trial researce group: a randomized trial of sorbinil, an aldose reductase inihibitor in diabetic retinopathy. Arch. Ophthalmol. 108: 1234-1244, 1990.
47. Knott R.M., Robertson M., Forrester I.V.: Regulation of glucose transporter (GLUT 3) and aldose reductase mRNA in bovine retinal endothelial cells and retinal pericytes in high glucose and high galactose culture. Diabetologia 36: 808-812, 1993.
48. Gabbay K.H.: Hyperglycaemia polyol metabolism and complications of diabetes mellitus. Annu. Rev. Med. 26: 521-536, 1975.
49. Stitt A.W., Anderson H.R., Gardiner T-A., Archer D.B.: Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br. J. Ophthalmol. 78: 133-137, 1994.
50. Lee W., Khatami M., Robertson G.A., Shen S., Rockey Y.H.: Non-enzymatic glycosylation of bovine retinal microvessel basement membranes in vitro. Invest. Ophthalmol. Visual. Sci 25: 884-892, 1984.
51. Shimomura H., Spiro R.G.: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36: 374-381, 1987.
52. Williamsons J.R., Tilton R.G., Chang K., Kilo C.: Basement membrane abnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes Metab. Rev. 4: 339-370, 1988.
53. Madri J.A., Williams S.K.: Capillary endothelial cells cultures phenotypic modulation by matrix components. J. Cell Biol. 97: 153-165, 1983.
54. Folkman J., Shing Y.: Angiogenesis. J. Cell Chem. 267: 10931-10934, 1994.
55. Ignotz R.A., Endo T., Massague J.: Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β. J. Biol. Chem. 262: 6443-6446, 1987.
56. Laiho M., Saksela O., Andreasen P.A., Keski-Oja J.: Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblast by transforming growth factor-β. J. Cell Biol. 103: 2403-2410, 1986.
57. Antonelli-Orlidge A., Saunders K.B., Smith S.R., D'Amore P.A.: An activated form of TGF-β is produced by co-culture of endothelial cells and pericytes. Proc. Natl. Acad. Sci. USA 86: 4544-4548, 1989.
58. Montesano R., Orci L., Vassalli P.: In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J. Cell Biol. 97: 1648-1652, 1983.
59. Roberts A.B., Anzano M.A.,Wakefield L.M., Roche N.S., Stern D.F., Sporn M.B.: Type β transforming growth factor, a bifunctional regulator of cell growth. Proc. Natl. Acad. Sci. USA 89: 119-123, 1985.
60. Pepper M.S., Beling D., Montesano R., Orci L., Vassalli J.D.: Transforming growth factor beta modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J. Cell Biol. 111: 743-755, 1990.
61. Muller G., Behrenz J., Nussbaumer U., Boehlen P., Bierchmeier W.: Inhibitory effect of transforming growth factor beta on endothelial cells. Proc. Natl. Acad. Sci. USA 84: 5600-5604, 1987.
62. Antoniades H.N.: PDGF: multifunctional growth factor. Clin. Endocrinol. Metab. 5: 595-613, 1991.
63. Norijuki K., Watanabe S., Tezuka M., Morisaki N., Saito Y., Yoshida S.: Migratory and proliferative effect of platelet derived growth factor in rabbit retinal endothelial cells: evidence of an autocrine pathway of platelet derived growth factor. J. Cell. Physiol. 158: 1-6, 1994.
64. Sato N., Beitz J.G., Kato J., Yahmahoto M., Clark J.W., Calabresi P., Raymond A., Frackelton A.R.Jr.: Platelet derived growth factor indirectly stimulates angiogenesis in vitro. Am. J. Pathol. 142: 1119-1130, 1993.
65. Harrison A.A., Dunbar P.R., Neable T.J.: Immunoassay of platelet derived growth factor in blood of patient with diabetes mellitus. Diabetologia 37: 1142-1146, 1994.
66. Caenazzo A., Pietrogrande F., Polato G., Piva E., Sartori D., Girolami A.: Decreased platelet mitogenic activity in patients with diabetes mellitus. Haematologia 24: 241-247, 1991.
67. Bach L.A., Recheler M.M.: Insulin-like growth factor and diabetes. Diab. Metab. Rev. 3: 228-257, 1992.
68. Grant M.B., Marnes R.N., Fritzgerald C.: Insulin-like growth factor-I acts as angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblasts growth factor. Diabetologia 36: 282-291, 1993.
69. Arnold D.R., Moshayedi P., Shoen T.J.: Distribution of IGF-I and IGF-II, IGF binding proteins (IGFBP) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in acqueous and vitreous. Exp. Eye Res. 56: 555-565, 1993.
70. Arner P., Sjoberg S., Gjotterberg M.: Circulating insulin-like growth factor-I in type I (insulin-dependent) diabetic patients with retinopathy. Diabetologia 32: 753-758, 1989.
71. Grant M.B., Caballero S., Millard W.J.: Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascolarization. Regul. Pept. 48: 267-278, 1993.
72. Jialal I., Crettaz M., Hachiya H.L.: Characterization of insulin and insulin-like growth factors on micro-and macrovascular tissue. Endocrinology 117: 1222-1229, 1985.
73. Grant M.B., Jerdan J., Merimee T.J.: Insulin-like growth factor-I modulates endothelial cells chemiotactic. J. Clin. Endocrinol. Metab. 65: 370-376, 1987.
74. Taylor W.R., Alexander R.W.: Autocrin control of wound repair by insulin-like growth factor-I in culture endothelial cells. Am. J. Physiol. C810-C805, 1993.
75. Bensaid M., Malecaze F., Prats H., Bayard F., Tauber J.P.: Autocrane regulation of bovine retinal capillary endothelial cells (BREC) proliferation by BREC-derived basic fibroblast growth factor. Exp. Eye Res. 48: 801-813, 1989.
76. Hearn M.T.: Structure and function of the heparin binding (fibroblast) growth factor family. Clin. Endocrinol. Metab. 5: 571-593, 1991.
77. Lobb R.R.: Thrombin inactivates acidic growth factor but not basic fibroblast growth factor. Biochemistry 27: 2572-2578, 1988.
78. Hanneken A., De Juan E.Jr, Lutty G.A., Fox G.M., Schiffer S., Hjelmeland L.M.: Altered distribution of fibroblast growth factor in diabetic retinopathy. Arch. Ophthalmol. 109: 1500-1511, 1991.
79. Sivalingam A., Kenney J., Brown G.C., Benson W.E., Donoso L.: Basic fibroblast growth factor level in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol. 108: 869-872, 1990.
80. Giardino I., Edelstein D., Brownlee M.: Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117, 1994.
81. Gragoudas E.S., Adamis A.P., D'Amico D.J., Yeo K.T., Brown L.F.: The role of vascular endothelial growth factor in pathologic ocular neovascularization: experimental and clinical investigations. Proc. XIXth Meeting of the Club Jules Gonin, Lausanne, Switzerland, Abs. 27, 1994 (Abstract).
82. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Janpel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park I.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331: 1480-1487, 1994.
83. Morise T., Takeuchi Y., Kawano M., Koni I., Takeda R.: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 18: 87-89, 1995.
84. Lieberman J., Sastre A.: Serum angiotensin converting enzyme elevation in diabetes mellitus. Ann. Intern. Med. 93: 825-826, 1980.
85. Wiemer G., Scholkens B.S., Becker R.H.A., Bussi R.: Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 18: 558-563, 1991.
86. Traub O., Van-Bibber R.: Role of nitric oxide in insulin dependent diabetes mellitus related vascular complications. West. J. Med 162: 439-445, 1995.
87. Dallinger K.J.C., Jennings P.E., Toop M.J., Clyde O.H.B., Barnett A.H.: Platelet aggregation and coagulation factors in insulin-dependent diabetics with and without microangiopathy. Diabetic Med. 4: 44-48, 1987.
88. 2 by diabetic platelets. Eur. J. Clin. Invest. 9: 223-228, 1979.
89. 2 release in normal and diabetic rats by the anthhrombotic compound Bay G 6375. Thromb. Res. 19: 663-670, 1980.
90. 1a-c: studies in diabetic patients and normal persons. Ann. Intern. Med 88: 311-316, 1978.
91. Porta M., Townsend C., Clover G., Nanson M., Alderson A.R., McCraw A., Kohner E.M.: Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 20: 597-601, 1981.
92. Morders D.B., Lazarchick J., Clowell J.A., Sens D.A.: Elevated glucose concentrations increase factor VIIIRAg levels in human umbilical vein endothelial cells. Diabetes 32: 876-878, 1983.
93. Cagliero E., Grant M.B., Lorenzi M.: Measurement of gene expression in human retinal microvessels by solution hybridization. Invest. Ophthalmol Vis. Sci. 32: 1439-1445, 1991.
94. Vague P., Juhan-Vague I., Aillaud M.F., Badier C., Viard R., Alessi M.C., Collen D.: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35: 250-252, 1986.
95. Almèr L.O., Pandolfi M.: Fibrinolysis and diabetic retinopathy. Diabetes 25 (Suppl. 2): 807-810, 1976.
96. Steffes M.W., Osterby R., Chavers B., Mauer S.M.: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077-1081, 1989.
97. Steffes M.W., Bilous R.W., Sutherland D.E.R., Mauer S.M.: Cell and matrix component of the glomeralar mesangium in type I diabetes. Diabetes 41: 679-684, 1992.
98. Mogensen C.E.: Glomerular filtration rate and renal plasma flow in short-term juvenile diabetes mellitus. Scand. J. Clin. Lab. Invest. 28: 91-100, 1971.
99. Pugliese G., Tilton R.G., Speedy A., Santarelli E., Eades D.M., Province M.A., Kilo C., Sherman W.R., Williamson J.R.: Modulation of hemodynamic and vascular filtration changes in diabetic rats by dietary myo-inositol. Diabetes 39: 312-322, 1990.
100. Pietravalle P., Morano S., Cristina G., De Rossi M.G., Mariant G., Cotroneo P., Ghirlanda G., Clementi A., Andreani D., Di Mario U.: Charge permselectivity of proteinuria in type 1 diabetes explored by immunoglobulin subclass clearance. Diabetes 40: 1685-1690, 1994.
101. Myers B.D.: Pathophysiology of proteinuria in diabetic glomerular disease. J. Hypertens. 8 (Suppl. 1): 541-546, 1990.
102. Fioretto P., Mauer M.: Hyperglycaemia and diabetic nephropathy. Diab. Nutr. Metab. 8: 166-173, 1995.
103. Roy S., Sala R., Cagliero E., Lorenzi M.: Overexpression of fibronectin induced by diabetes or high glucose: a phenomenon with a memory. Proc. Natl. Acad. Sci. USA 87: 404-408, 1990.
104. Wakisaka M., Spiro M.J., Spiro R.: Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 43: 95-103, 1994.
105. Kanwar Y.S., Rosenweig L.J., Linker A., Jakubowski M.L.: Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and autoradiographic evidence. Proc. Natl. Acad. Sci. USA 80: 2272-2275, 1983.
106. Lubec G., Pollak A.: Reduced susceptibility of nonenzymatically glycosylated glomerular basement membrane to proteases: is thickening of diabetic glomerular basement membranes due to reduced proteolytic degradation? Renal Physiol. 3: 4-8, 1980.
107. Tarsio J.F., Reger L.A., Furcht L.T.: Molecular mechanisms in basement membrane complications in diabetes: alterations in heparin, laminin and type IV collagen association. Diabetes 37: 532-539, 1988.
108. Fukui M., Nakamura T., Ebihara I., Shirato I., Tomino Y., Koide H.: ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 41: 1520-1527, 1992.
109. Danne T., Spiro M.J., Spiro R.: Effect of high glucose on type IV collagen production by cultured glomerular epithelial, endothelial and mesangial cells. Diabetes 42: 170-177, 1993.
110. Pugliese G., Pricci F., Pugliese F., Mene P., Lenti L., Andreani D., Galli G., Casini A., Bianchi S., Rotella C.M., Di Mario U.: Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 43: 478-490, 1994.
111. Pricci F., Pugliese G., Romano G., Romeo G., Locuratolo N., Mene P., Pugliese F., Galli G., Casini A., Rotella C.M., Di Mario U.: Insulin-like growth factor (IGF)-I and IGF-II stimulate extracellular matrix production in human mesangial cells. Comparison with transforming growth factor-β (TGF-β). Endocrinology 137: 879-885, 1996.
112. Pugliese G., Pricci F., Locuratolo N., Romeo G., Romano G., Giannini S., Cresci B., Galli G., Rotella C.M., Di Mario U.: Increased activity of the insulin-like growth factor system in mesangial cells cultured in high glucose conditions: relation to glucose-enhanced extracellular matrix production. Diabetologia 39: 775-784, 1996.
113. Studer R.K., Craven P.A., De Rubertis F.R.: Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high glucose medium. Diabetes 42: 118-126, 1993.
114. Doi T., Vlassara H., Kirstein M., Yamada Y., Striker G.E., Striker L.J.: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 89: 2873-2877, 1992.
115. Morgensen C.E., Christensen C.K.: Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 311: 89-93, 1984.
116. Ballerman B.J., Zeidel M.L., Gunning M.E., Brenner B.M.: Vasoactive peptides and the kidney. In: Benner B.M., Rector F.C. (Eds), The kidney, ed. 4. Saunders, Philadelphia, 1991, pp. 510-583.
117. Doria A., Warram J.H., Krolewski A.S.: Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 43: 690-695, 1994.
118. Lewis E.J., Hunsicker L.G., Bain R.B., Rhode R.D.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329: 1456-1462, 1993.
119. Maschio G.: The effect of antihypertensive treatment on the course of diabetic nephropathy. Diab. Nutr. Metab. 8: 179-184, 1995.
120. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F.E., Motolese M., Ponticelli C., Ritz E., Zucchelli P., and the angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. EngL J. Med. 334: 939-945, 1996.
121. Lash J.P., Bakris G.L.: Effect of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol. Dial. Transplant. 10 (Suppl. 9): 56-62, 1995.
122. Anderson S., Rennke H.G., Garcia D.L., Brenner B.M.: Short and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 36: 526-536, 1989.
123. Connolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L., Del Fino J.J., Siegel N.R., Leimgruber R.M., Feder J.: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84: 1470-1478, 1989.
124. Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G.: The binding of vascular endothelial growth factor to its receptor is dependent on cell-surface associated heparin-like molecules. J. Biol. Chem. 267: 6093-6098, 1992.
125. Gomez-Garre D., Ruitz-Ortega M., Ortego M., Largo R., Lopez-Armada M.J., Plaza J.J., Gonzales E., Egido J.: Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 27: 885-892, 1996.
126. Ruitz-Ortega M., Gomez-Garre D., Alcazar R., Palacios I., Bustos C., Gonzales S., Plaza J.J., Gonzales E., Egidio J.: Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J. Hypertens. 12: S51-S58, 1994.
127. Thaiss F., Qolfe G., Assad N., Zahuer G., Stahl R.A.K.: Angiotensinase A gene expression and enzyme activity in isolated glomeruli of diabetic rats. Diabetologia 39: 275-280, 1996.
128. Katoh T., Chang H., Uchida S., Okuda T., Kurokawa K.: Direct effects of endothelin in the rat kidney. Am. J. Physiol. 258: F397-F402, 1990.
129. Simonson M.S., Dunn M.J.: Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates β-adrenergic-mediated cyclic adenosine monophosphate accumulation. J. Clin. Invest. 85: 790-797, 1990.
130. Nakamura T., Ebihara I., Fukui M., Tomino Y., Koide H.: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44: 895-899, 1995.
131. Benigni A., Perico N., Gaspari F., Zoja C., Bellizzi L., Gabanelli M., Remuzzi G.: Increased renal endothelin production in rats with reduced renal mass. Am. J. Physiol. 260: F331-F339, 1991.
132. Orisio S., Benigni A., Bruzzi I., Corna D., Perico N., Zoja C., Benatti L., Remuzzi G.: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 43: 354-358, 1993.
133. Lee Y.-J., Shin S.-J., Tsai J.-H.: Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care 17: 263-266, 1994.
134. Andreani D.: The labyrinth of diabetic vascular disease: Grassroads and ways out. Diab. Nutr. Metab. 8: 54-64, 1995.
135. Lams K.S., Cheng I.K.P., Janus E.D., Pang R.W.: Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38: 604-609, 1995.
136. Nosadini R.: Symposium on diabetic nephropathy. Introduction. Diab. Nutr. Metab. 8: 129-133, 1995.
137. Trevisan R., Viberti G.C.: Genetic predisposition and diabetic nephropathy. Diab. Nutr. Metab, 8: 159-165, 1995.
138. Plater M.E., Ford I., Dent M.T., Preston P.E., Ward J.D.: Elevated von Willebrandt factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 39: 336-343, 1996.
139. Spiro M.J., Kumar B.R.R., Crowley T.J.: Myocardial glycoproteins in diabetes: types VI collagen is a major PAS-reactive extracellular matrix protein. J. Mol. Cell. Cardiol. 24: 339-410, 1992.
140. Spiro M.J., Crowley T.J.: Increased rat myocardial type VI collagen in diabetes mellitus and hypertension. Diabetologia 36: 93-98, 1993.
141. Spiro M.J., He Q., D'Autilia M.L.: Effect of high glucose on formation of extracellular matrix components by cultured rat heart endothelial cells. Diabetologia 38: 430-436, 1995.
142. Klein D.J., Cohen R.M., Rymaszewski Z.: Proteoglycan synthesis by bovine myocardial endothelial cells is increased by long-term exposure to high concentrations of glucose. J. Cell. Physiol. 165: 493-502, 1995.
143. Flynn M.D., Tooke J.E.: Aetiology of diabetic foot ulceration: a role for the microcirculation? Diabetic Med. 9: 320-329, 1992.
144. Flynn M.D., Tooke J.E.: Diabetic neuropathy and the microcirculation. Diabetic Med. 12: 298-301, 1995.